Insulet (NASDAQ:PODD) Posts Quarterly Earnings Results, Beats Expectations By $0.15 EPS

Insulet (NASDAQ:PODD) posted its quarterly earnings results on Thursday. The medical instruments supplier reported $1.15 EPS for the quarter, beating the consensus estimate of $1.00 by $0.15, Zacks reports. The business had revenue of $597.50 million during the quarter, compared to analyst estimates of $582.02 million. Insulet had a net margin of 21.22% and a return on equity of 27.98%. Insulet updated its Q1 2025 guidance to EPS and its FY 2025 guidance to EPS.

Insulet Stock Performance

PODD stock traded down $7.31 during trading on Friday, reaching $280.98. 587,399 shares of the stock were exchanged, compared to its average volume of 548,873. The company has a market capitalization of $19.71 billion, a P/E ratio of 48.11, a price-to-earnings-growth ratio of 3.56 and a beta of 1.23. Insulet has a twelve month low of $160.19 and a twelve month high of $289.46. The stock has a 50 day simple moving average of $272.71 and a 200-day simple moving average of $246.47. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on PODD shares. JPMorgan Chase & Co. lifted their target price on Insulet from $280.00 to $330.00 and gave the company an “overweight” rating in a research note on Thursday, December 12th. Stifel Nicolaus boosted their price objective on Insulet from $245.00 to $293.00 and gave the company a “hold” rating in a research report on Friday. Raymond James reaffirmed an “outperform” rating and issued a $328.00 target price (up from $294.00) on shares of Insulet in a research report on Friday. Wells Fargo & Company boosted their price target on shares of Insulet from $305.00 to $322.00 and gave the company an “overweight” rating in a report on Friday. Finally, Piper Sandler increased their price objective on shares of Insulet from $285.00 to $310.00 and gave the stock an “overweight” rating in a report on Friday. Three investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $286.25.

Insider Activity

In other Insulet news, CAO Lauren Budden sold 915 shares of the company’s stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total transaction of $252,192.30. Following the sale, the chief accounting officer now directly owns 5,733 shares of the company’s stock, valued at approximately $1,580,129.46. This represents a 13.76 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Eric Benjamin sold 12,394 shares of Insulet stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the completion of the transaction, the executive vice president now owns 11,383 shares of the company’s stock, valued at $3,187,240. This trade represents a 52.13 % decrease in their position. The disclosure for this sale can be found here. 0.47% of the stock is owned by company insiders.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.